Market Cap 12.00M
Revenue (ttm) 11.00M
Net Income (ttm) -69.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.36%
Debt to Equity Ratio 0.00
Volume 990,100
Avg Vol 2,719,320
Day's Range N/A - N/A
Shares Out 63.46M
Stochastic %K 17%
Beta 1.08
Analysts Hold
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
tmpl
tmpl Mar. 11 at 11:08 PM
$BCAB Looked into yesterday's Cntx conference, Context specifically praised BCAB's (CAB) technology, stated they fully funded to advance CT-202 (the Nectin-4 x CD3 bispecific antibody they licensed from BioAtla). This is a strong support for BCAB's value, and it increases the BO potential. Pfizer as the leader in Nectin-4 might be the most candidate. Fingers crossed🙏
0 · Reply
winners3628
winners3628 Mar. 11 at 9:03 PM
$BCAB https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/guest_book?session_id=XG5T44wDZtFqK3hid5hfLz
0 · Reply
winners3628
winners3628 Mar. 11 at 3:49 PM
$BCAB Cntx conference yesterday indicated partnered bcab tce to be in clinic soon!
1 · Reply
Gator5326
Gator5326 Mar. 11 at 1:10 PM
0 · Reply
biovaluable
biovaluable Mar. 11 at 1:03 PM
$BCAB remember. Yorkville's exit plan!
1 · Reply
Misterx69
Misterx69 Mar. 11 at 3:15 AM
0 · Reply
eruizgon
eruizgon Mar. 10 at 11:21 PM
0 · Reply
Gator5326
Gator5326 Mar. 10 at 7:16 PM
0 · Reply
tmpl
tmpl Mar. 10 at 5:24 PM
$BCAB Hello? Is there anybody in there? Just nod if you can hear me Is there anyone home? Come on now I hear you're feeling down Well, I can ease your pain And get you on your feet again Relax I'll need some information first Just the basic facts Can you show me where it hurts?
0 · Reply
Misterx69
Misterx69 Mar. 10 at 4:26 PM
0 · Reply
Latest News on BCAB
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 6:51 PM EST - 4 months ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:43 AM EDT - 7 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 5:55 PM EDT - 11 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript


BioAtla to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 11 months ago

BioAtla to Participate in the Citizens Life Sciences Conference


BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:18 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript


BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort


BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript


BioAtla: Numerous Catalysts Coming In Q4

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4


BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript


BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 2, 2024, 10:03 AM EDT - 2 years ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024


BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:21 PM EDT - 2 years ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript


tmpl
tmpl Mar. 11 at 11:08 PM
$BCAB Looked into yesterday's Cntx conference, Context specifically praised BCAB's (CAB) technology, stated they fully funded to advance CT-202 (the Nectin-4 x CD3 bispecific antibody they licensed from BioAtla). This is a strong support for BCAB's value, and it increases the BO potential. Pfizer as the leader in Nectin-4 might be the most candidate. Fingers crossed🙏
0 · Reply
winners3628
winners3628 Mar. 11 at 9:03 PM
$BCAB https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/guest_book?session_id=XG5T44wDZtFqK3hid5hfLz
0 · Reply
winners3628
winners3628 Mar. 11 at 3:49 PM
$BCAB Cntx conference yesterday indicated partnered bcab tce to be in clinic soon!
1 · Reply
Gator5326
Gator5326 Mar. 11 at 1:10 PM
0 · Reply
biovaluable
biovaluable Mar. 11 at 1:03 PM
$BCAB remember. Yorkville's exit plan!
1 · Reply
Misterx69
Misterx69 Mar. 11 at 3:15 AM
0 · Reply
eruizgon
eruizgon Mar. 10 at 11:21 PM
0 · Reply
Gator5326
Gator5326 Mar. 10 at 7:16 PM
0 · Reply
tmpl
tmpl Mar. 10 at 5:24 PM
$BCAB Hello? Is there anybody in there? Just nod if you can hear me Is there anyone home? Come on now I hear you're feeling down Well, I can ease your pain And get you on your feet again Relax I'll need some information first Just the basic facts Can you show me where it hurts?
0 · Reply
Misterx69
Misterx69 Mar. 10 at 4:26 PM
0 · Reply
JA1950
JA1950 Mar. 10 at 2:57 PM
$BCAB I was bullish yesterday. They was before the filing last evening. Selling 1M shares to raise $154K is not encouraging. They cut 70% of their workforce three weeks ago and expected to pay off the severance by March 31. Raising $154K tells me they won't have enough money to run a proper asset sale by Tungsten. They should have started this process January 1 when they had $7.1M in cash. I'm out.
1 · Reply
biovaluable
biovaluable Mar. 10 at 2:36 PM
$BCAB death spiral by yorkville
0 · Reply
Misterx69
Misterx69 Mar. 10 at 2:12 PM
0 · Reply
Gator5326
Gator5326 Mar. 10 at 1:43 PM
0 · Reply
biovaluable
biovaluable Mar. 10 at 6:25 AM
$BCAB Currently, the number of listed shares is 81,170,430. It's almost doubled compared to the middle of last year! Infinite dilution!
0 · Reply
biovaluable
biovaluable Mar. 10 at 6:24 AM
$BCAB AIRC wouldn't have put in a $5M down payment by January 30th. No disclosure, no content anywhere in the 8k report. It's just ruined. A delisting scenario after infinitely diluting with SEPA.
0 · Reply
biovaluable
biovaluable Mar. 10 at 6:23 AM
$BCAB Yorkville`s exit planning!
0 · Reply
biovaluable
biovaluable Mar. 10 at 12:15 AM
$BCAB After working for over 13 years, the CFO was fired, and Jay's personal assistant is now acting as CFO. Judging from the execution of the SEPA contract 1. The company is completely out of funds. 2. There is no capital or company interested in this company's assets. You can guess. They inflated the PPA/SEPA contract in November last year as if they had a counterparty. And look at the end of the companies that started the death spiral! Yorkville money. Mostly delisting.
0 · Reply
biovaluable
biovaluable Mar. 10 at 12:13 AM
$BCAB Beware, management is unethical. Their RSU tax treatment came around $0.247, when the stock was at a short high. Really bad management and owners.
1 · Reply
biovaluable
biovaluable Mar. 10 at 12:12 AM
$BCAB Yorkeville received 931,032 shares at $0.166 per share under the SEPA contract. Yorkeville also sold in the PPA contract right after the stock conversion. There could be a huge amount of potential offerings. Also, the total issued shares specified in this report is 81,170,430. Excluding Yorkeville's quantity, we can see that all of anson's PPA has already been converted into shares. Probably they exited last week when they rose $0.23. This is because the SEC equity report is not coming out. The $154,000 secured by the first SEPA sale this time is far short. The company is on the verge of a beggar bankruptcy.
0 · Reply
JA1950
JA1950 Mar. 9 at 7:21 PM
$BCAB I am loading up between $.15-20/sh. No debt, 70% workforce reduction, and expectation that they have $3-5M in cash should be enough runway for Tungsten to run an orderly auction/sale. Distressed, this is worth $50M. I hope they can get $100M for all assets over time, which is $1.25/sh, or 5-7x. ANY sale of ANY asset will be sufficient to move the stock back toward $1 as it will indicate momentum and value. If there is a path toward funding the Phase III trial through the SPV, this is a $2/sh stock. But base case, this is $.40-50 IMO. NFA/DYOR
0 · Reply
Misterx69
Misterx69 Mar. 9 at 3:06 PM
0 · Reply